CN104334166A - 用于预防和治疗精神、行为和认知障碍的药物组合物 - Google Patents

用于预防和治疗精神、行为和认知障碍的药物组合物 Download PDF

Info

Publication number
CN104334166A
CN104334166A CN201280073167.XA CN201280073167A CN104334166A CN 104334166 A CN104334166 A CN 104334166A CN 201280073167 A CN201280073167 A CN 201280073167A CN 104334166 A CN104334166 A CN 104334166A
Authority
CN
China
Prior art keywords
melatonin
memantine
weight
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201280073167.XA
Other languages
English (en)
Chinese (zh)
Inventor
玛加丽塔·阿列克谢耶芙娜·莫罗佐娃
艾伦·格罗维奇·本尼亚什威利
马克西姆·爱德华多维奇·扎波尔斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wahlen Tower Co Ltd
Original Assignee
Wahlen Tower Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wahlen Tower Co Ltd filed Critical Wahlen Tower Co Ltd
Publication of CN104334166A publication Critical patent/CN104334166A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280073167.XA 2012-05-24 2012-10-31 用于预防和治疗精神、行为和认知障碍的药物组合物 Withdrawn CN104334166A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2012121410/15A RU2488388C1 (ru) 2012-05-24 2012-05-24 Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
RU2012121410 2012-05-24
PCT/RU2012/000888 WO2013176567A1 (ru) 2012-05-24 2012-10-31 Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств

Publications (1)

Publication Number Publication Date
CN104334166A true CN104334166A (zh) 2015-02-04

Family

ID=49155569

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280073167.XA Withdrawn CN104334166A (zh) 2012-05-24 2012-10-31 用于预防和治疗精神、行为和认知障碍的药物组合物

Country Status (14)

Country Link
US (1) US20150157604A1 (cg-RX-API-DMAC7.html)
EP (1) EP2857011A4 (cg-RX-API-DMAC7.html)
JP (1) JP5864819B2 (cg-RX-API-DMAC7.html)
KR (1) KR101581611B1 (cg-RX-API-DMAC7.html)
CN (1) CN104334166A (cg-RX-API-DMAC7.html)
AU (1) AU2012380583B2 (cg-RX-API-DMAC7.html)
CA (1) CA2873891C (cg-RX-API-DMAC7.html)
EA (1) EA201400973A1 (cg-RX-API-DMAC7.html)
HK (1) HK1205467A1 (cg-RX-API-DMAC7.html)
IL (1) IL235852A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN09940A (cg-RX-API-DMAC7.html)
RU (1) RU2488388C1 (cg-RX-API-DMAC7.html)
UA (1) UA112352C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013176567A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109414418A (zh) * 2016-06-29 2019-03-01 瓦伦塔有限责任公司 包含美金刚和褪黑素的组合的药物组合物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2536270C1 (ru) * 2013-10-21 2014-12-20 Общество с ограниченной ответственностью ООО "ВАЛЕНТА ИНТЕЛЛЕКТ" Комбинация для коррекции неврологического и психоэмоционального статуса при органических нарушениях цнс
CN115569282A (zh) 2015-11-24 2023-01-06 麻省理工学院 用于预防、减轻和/或治疗痴呆的系统和方法
RU2623865C1 (ru) * 2016-06-29 2017-06-29 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
RU2654713C1 (ru) * 2016-06-29 2018-05-22 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, содержащая комбинацию мемантина и мелатонина
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
PT3337462T (pt) * 2016-10-31 2020-10-30 Neurim Pharmaceuticals 1991 Ltd Minicomprimidos de melatonina e método de fabrico dos mesmos
JP7082334B2 (ja) 2016-11-17 2022-06-08 コグニート セラピューティクス，インク． 視覚刺激を介した神経刺激のための方法およびシステム
US11241586B2 (en) 2017-10-10 2022-02-08 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia
US10960225B2 (en) * 2017-10-10 2021-03-30 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034134A (en) * 1997-06-30 2000-03-07 Merz + Co. Gmbh & Co. 1-Amino-alkylcyclohexane NMDA receptor antagonists
WO2006009769A1 (en) * 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
US20090306200A1 (en) * 2005-04-04 2009-12-10 Takeda Pharmaceutical Company Limited Prophylactic or Therapeutic Agent for Nocturnal Conduct Disorder Associated With Dementia

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7305644A (cg-RX-API-DMAC7.html) 1972-04-20 1973-10-23
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
DE10299048I2 (de) 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
DK1562585T3 (da) 2002-10-30 2011-03-14 Asat Ag Applied Science & Tech Daglige melatonindoseringsenheder
RU2268737C2 (ru) 2004-02-16 2006-01-27 Государственное учреждение институт клинической иммунологии СО РАМН Способ лечения атопического дерматита
EP1841460A2 (en) * 2004-06-18 2007-10-10 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
CN101374525A (zh) * 2004-09-23 2009-02-25 莫茨药物股份两合公司 美金刚治疗儿童行为障碍
CN1709230A (zh) * 2005-07-05 2005-12-21 北京阜康仁生物制药科技有限公司 盐酸美金刚分散片及其制备方法
RU2294741C1 (ru) 2005-08-08 2007-03-10 Рина Михайловна Заславская Способ лечения больных ишемической болезнью сердца, стабильной стенокардией в сочетании с артериальной гипертонией
KR20090029200A (ko) * 2006-05-22 2009-03-20 반다 파마슈티칼즈, 인코퍼레이티드. 우울증 질환에 대한 치료
EP2029564A4 (en) * 2006-05-22 2010-01-13 Vanda Pharmaceuticals Inc TREATMENT OF DEPRESSIVE DISORDERS
CA2654523A1 (en) * 2006-07-05 2008-01-10 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of memantine
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine
GB0623897D0 (en) * 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
RU2326660C1 (ru) 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
MX2009010878A (es) 2007-04-11 2010-03-26 John A Mccarty Pastilla de melatonina y metodos de preparacion y uso.
AU2008240211A1 (en) 2007-04-12 2008-10-23 Regents Of The University Of Minnesota Ischemia/reperfusion protection compositions and methods of using
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2010089132A1 (en) * 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
RU2394571C1 (ru) 2009-05-14 2010-07-20 Государственное бюджетное учреждение здравоохранения города Москвы "Городская клиническая больница № 24" Департамента здравоохранения города Москвы Способ лечения воспалительных заболеваний кишечника
RU2418586C2 (ru) 2009-06-11 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Новосибирский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО НГМУ Росздрава) Способ коррекции нарушений в репродуктивных органах, вызванных высокой температурой
RU2428183C1 (ru) 2010-07-01 2011-09-10 Рина Михайловна Заславская Адаптоген для метеочувствительных больных стенокардией и артериальной гипертензией и применение мелатонина в качестве адаптогена

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034134A (en) * 1997-06-30 2000-03-07 Merz + Co. Gmbh & Co. 1-Amino-alkylcyclohexane NMDA receptor antagonists
WO2006009769A1 (en) * 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
US20090306200A1 (en) * 2005-04-04 2009-12-10 Takeda Pharmaceutical Company Limited Prophylactic or Therapeutic Agent for Nocturnal Conduct Disorder Associated With Dementia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DEBOMOY K. LAHIRI ET AL.: "Amyloid, Cholinesterase, Melatonin, and Metals and Their Roles in Aging and Neurodegenerative Diseases", 《ANN. N.Y. ACAD. SCI.》, vol. 1056, no. 1, 31 December 2005 (2005-12-31) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109414418A (zh) * 2016-06-29 2019-03-01 瓦伦塔有限责任公司 包含美金刚和褪黑素的组合的药物组合物

Also Published As

Publication number Publication date
IL235852A0 (en) 2015-01-29
UA112352C2 (uk) 2016-08-25
EA201400973A1 (ru) 2015-02-27
JP2015517569A (ja) 2015-06-22
CA2873891A1 (en) 2013-11-28
EP2857011A4 (en) 2015-12-02
AU2012380583B2 (en) 2015-01-22
HK1205467A1 (en) 2015-12-18
WO2013176567A1 (ru) 2013-11-28
US20150157604A1 (en) 2015-06-11
KR20150005999A (ko) 2015-01-15
AU2012380583A1 (en) 2014-12-18
EP2857011A1 (en) 2015-04-08
JP5864819B2 (ja) 2016-02-17
CA2873891C (en) 2016-02-16
RU2488388C1 (ru) 2013-07-27
KR101581611B1 (ko) 2015-12-31
IN2014DN09940A (cg-RX-API-DMAC7.html) 2015-08-14

Similar Documents

Publication Publication Date Title
JP5864819B2 (ja) 精神的障害、行動障害および認知障害の予防および治療のための医薬組成物
US11318144B2 (en) Compositions and methods for treating Alzheimer's disease and Parkinson's disease
CN102573823B (zh) 包含反式去甲舍曲林和血清素受体1a激动剂/拮抗剂的组合物及其用途
CN101657194B (zh) 包含葫芦巴碱和4-羟基异亮氨酸的药物组合物及其方法
US12138242B1 (en) Controlling neuropathic pain
JP2012500283A (ja) （ｒ）−プラミペキソールを使用した組成物並びにその方法
JP2021080276A (ja) デクスメデトミジン製剤を使用する睡眠障害の予防または治療
CN115776885A (zh) 用于治疗阿尔茨海默病和帕金森病的组合物和方法
CN113924098A (zh) 治疗精神障碍、行为障碍、认知障碍的方法
CN112957334B (zh) 含alpelisib的药物组合物
JP2020511455A (ja) 医薬組成物およびその使用
US20220193043A1 (en) Pharmaceutical Combination Formulations Comprising Tizanidine, Resveratrol and Piperine
CN120837494A (zh) 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
EP2905021B1 (en) Combination for the prophylaxis and treatment of behavioural, mental and cognitive disorders
CN113613653A (zh) 治疗边缘型人格障碍的方法
US20250352603A1 (en) Valerian composition for sleep management
US20200022951A1 (en) Multivitamin composition for improving verbal fluency, decreasing performance anxiety symptoms and method for preparing same
KR20240070564A (ko) 알츠하이머병 예방 또는 치료용 약학적 조성물
HK40084155A (en) Pharmaceutical compositions comprising alpelisib
CN111939139A (zh) 一种盐酸美金刚缓释和盐酸多奈哌齐速释胶囊及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1205467

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1205467

Country of ref document: HK

C04 Withdrawal of patent application after publication (patent law 2001)
WW01 Invention patent application withdrawn after publication

Application publication date: 20150204